=
꿇
虩
ب
_
5

OIP	E JOY
JUL.	1200 E
12	Under Panerwor

PTO/SB/30 (01-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE k Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Request For

Continued Examination (RCE) **Transmittal**

Address to: Commissioner for Patents **Box RCE** Washington, DC 20231


Application Number	10/047,578	
Filing Date	October 26, 2001	
First Named Inventor	Jeffrey S. Kiel	
Art Unit	1614	
Examiner Name	Brian Kwon	
Attorney Docket Number	PEDI-04	

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Requestf or Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1.	Submis		
	a	Previously submitted	
	i.	Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on _ (Any unentered amendment(s) referred to above will be entered).	
	fi.	Consider the arguments in the Appeal Brief or Rely Brief previously filed on	
	tii.	Other	
	b. 🗸	Enclosed	
	1.	✓ Amendment/Reply iii. Information	Disclosure Statement (IDS)
	ii.	Affidavit(s)/ Declaration(s) iv. Other	
. [Miscella	laneous	
,		Suspension of action on the above-identified application is requested under 37 C	FR 1.103(c) for a
	a. [_]	period of months.(Period of suspension shall note xceed 3 months; Fee under Other	er 37 CFR 1.17(i) required)
	a b	period of months.(Period of suspension shall note xceed 3 months; Fee under	er 37 CFR 1.17(i) required)
. (b. Fees	Other The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is	is filed.
. (b. Fees a.	Other	is filed.
. (Other The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE in The Director is hereby authorized to charge the following fees, or credit any over	is filed.
. (a. 🗸	Other The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE The Director is hereby authorized to charge the following fees, or credit any overpoposit Account No. 23-3000	is filed.
. (a. 🗸 i.	Other The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE in The Director is hereby authorized to charge the following fees, or credit any overy Deposit Account No. 23-3000 RCE fee required under 37 CFR 1.17(e)	is filed.
. (a. 🗸 i. ii.	Other The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is The Director is hereby authorized to charge the following fees, or credit any overposit Account No. 23-3000 RCE fee required under 37 CFR 1.17(e) Extension of time fee (37 CFR 1.136 and 1.17) ✓ Other Any additional fees or surcharges deemed due	is filed.
. (a.	Other The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is The Director is hereby authorized to charge the following fees, or credit any overy Deposit Account No. 23-3000 RCE fee required under 37 CFR 1.17(e) Extension of time fee (37 CFR 1.136 and 1.17) Other Any additional fees or surcharges deemed due Check in the amount of \$ 860.00 enclosed (1	is filed. payments, to
. (a.	Other The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is The Director is hereby authorized to charge the following fees, or credit any oversupposit Account No. 23-3000 RCE fee required under 37 CFR 1.17(e) Extension of time fee (37 CFR 1.136 and 1.17) Other Any additional fees or surcharges deemed due Check in the amount of \$ 860.00 enclosed (1) Payment by credit card (Form PTO-2038 enclosed)	is filed. payments, to RCE fee plus 3 mo. ext. of time)
. (a.	Other The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is The Director is hereby authorized to charge the following fees, or credit any overy Deposit Account No. 23-3000 RCE fee required under 37 CFR 1.17(e) Extension of time fee (37 CFR 1.136 and 1.17) Other Any additional fees or surcharges deemed due Check in the amount of \$ 860.00 enclosed (1	is filed. payments, to RCE fee plus 3 mo. ext. of time) formation should not
. (a.	Other The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE in The Director is hereby authorized to charge the following fees, or credit any overy Deposit Account No. 23-3000 RCE fee required under 37 CFR 1.17(e) Extension of time fee (37 CFR 1.136 and 1.17) ✓ Other Any additional fees or surcharges deemed due Check in the amount of \$ 860.00 enclosed (1) Payment by credit card (Form PTO-2038 enclosed) WARNING: Information on this form may become public. Credit card information and authorize	RCE fee plus 3 mo. ext. of time) formation should not ation on PTO-2038.
lame	a.	Other The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE in The Director is hereby authorized to charge the following fees, or credit any overy Deposit Account No. 23-3000 RCE fee required under 37 CFR 1.17(e) Extension of time fee (37 CFR 1.136 and 1.17) ✓ Other Any additional fees or surcharges deemed due Check in the amount of \$ 860.00 enclosed (1) Payment by credit card (Form PTO-2038 enclosed) WARNING: Information on this form may become public. Credit card information and authorized included on this form. Provide credit card information and authorized included on this form. Provide credit card information and authorized included in the provide credit card information and authorized included in the provide credit card information and authorized included in the provide credit card information and authorized included in the provide credit card information and authorized in the provide credit card in the provide credit	RCE fee plus 3 mo. ext. of time) formation should not ation on PTO-2038.

Name (Print/Type) \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	E. Jetteries			Registra	ition N	O. (Att	omey/Agent	/ 146,800	
Signature	JULEC	2		Date	7 2	20/0	4		
	200	CERTIFICATE	OF MAILING OR TH	RANSMISSION					
I hereby certify that this corres addressed to: Commissioner F shown below.									
Name (Print/Type)	GER M.GR	AFF On					1		
Signature 4	VOICE M.S	MALK		Date	7	1201	04		
<u> </u>	- 		Page Lof 2			, -	,		

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Box RCE,W ashington, DC 20231.



by to Office Action dated December 23, 2003

An endme Redy to O

PATENT

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on July 20, 2004.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No:

10/047,578

Filed:

October 26, 2001

Applicant: Title:

Jeffrey S. Kiel et al. PHENYLEPHRINE TANNATE AND PYRILAMINE TANNATE

SALTS IN PHARMACEUTICAL COMPOSITIONS

Art Unit:

1614

Confirmation No:

4696

Examiner:
Attorney Docket:

Brian Kwon PEDI-04 (formerly KIEL-02)

Cincinnati, Ohio 45202

July 20, 2004

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUBMISSION FOR REQUEST FOR CONTINUED EXAMINATION UNDER 37 CFR § 1.114

In response to the Office Action dated December 23, 2003, in the aboveidentified application, Applicant responds as follows:

Amendments to the Claims are reflected in the Listing of Claims which begins on page 2 of this paper.

Remarks begin on page 14 of this paper.